MMAVAX | Linksium
Back to portfolio

MMAVAX

Maturation

Insurance for immunotherapy of Pseudomonas aeruginosa infections

profilePhoto   Valentine Panel
Linksium Contact Valentine Panel +33 (0)6 35 81 73 67 valentine.panel@linksium.fr
MMAVAX unsplash

Benefits

  • Varied humoral response
  • Complete Clearance
  • Cystic fibrosis
  • COPD

Key words

  • Vaccine
  • Pseudomonas aeruginosa
  • Dead but metabolically active bacteria

Intellectual Property

  • 1 patent

Laboratory

  • TIMC

Institution

  • UGA

Linksium Continuum

  • Maturation

Context

In respiratory infections caused by Pseudomonas aeruginosa (Pa), curative treatments such as antibiotics are not sufficient to eradicate Pa due to resistance phenomena and the different vaccine strategies tested to date have not demonstrated their effectiveness.

Technology

The strategy is based on the development of a dead but metabolically active bacterium (MMA) that both (i) positively controls the expression of SST3 for a varied humoral response against different antigens, and (ii) strongly activates the secretion of Il-17 stimulating the Th17-type response necessary for the complete clearance of Pa from the lungs.

Advantages

This dual targeting strategy for MMAVAX vaccine is intended to ensure any possible escape from Pa eradication in the affected patient.
In addition, the patented technology prevents any possibility of counterfeiting MMAVAX vaccine because it is not replicable once formulated into a vaccine dose and distributed.

State of progress

The modified and attenuated Pa strain was constructed in the laboratory. It was subjected to several in vitro and in vivo tests that confirmed its efficacy. We are currently working on producing the product on scales more compatible with industrial conditions.

Applications

We envision that MMAVAX vaccine will be used as a first-line treatment in populations at risk of Pa infection such as (i) cystic fibrosis, (ii) chronic obstructive pulmonary disease (COPD) or (iii) patients scheduled for major surgery in the hospital.

In the magazine

Nora Dempsey and deeptech innovations

1, 2 and 3 startups for Nora Dempsey, National Medal of Innovation 2021

Nora Dempsey is one of the four winners of National Medal for Innovation 2021 awarded by CNRS. Nora Dempsey, born in Ireland, has gained an international recognition for her research in Grenoble on...

Read the article
Dd amiral 2018 Frenchweb

Amiral Technologies, la startup IA grenobloise spécialisée dans les solutions de maintenance prédictive, intègre Station F

An ambitious promise: to invent a zero-defect and zero-downtime future for industry. Amiral Technologies, a startup co-founded and boosted by Linksium, based on the technological prowess of the Gre...

Read the article